Anti-Mouse CD73 – Purified in vivo PLATINUM™ Functional Grade

BALB/c mouse splenocytes and CHO cells transfected with the mouse CD73 gene

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM^TM antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

Ty/23 activity is directed against mouse CD73, also known as ecto-5′-nucleotidase (5′-NT).

CD73 is a 69 kDa cell-surface protein anchored to the membrane by a GPI (glycosylphosphatidylinositol) anchor. CD73 plays a vital role in modulating the immune response by converting AMP (adenosine monophosphate) to adenosine. This conversion shifts the environment from being pro-inflammatory to anti-inflammatory. CD73 is particularly involved in the immunosuppressive activity of regulatory T cells. It catalyzes the dephosphorylation of extracellular nucleoside 5' monophosphates to nucleosides^1,2. CD73 is expressed on specific subsets of T and B lymphocytes, with the highest expression found on B cells and CD8+ T cells. It is also implicated in cell activation, lymphocyte homing, and cell adhesion³. Moreover, CD73 has protective functions in various organ systems and cell types. For instance, it plays anti-nociceptive roles in the central nervous system and barrier-preserving roles in the respiratory system⁴.

The TY/23 clone has been demonstrated to inhibit the enzymatic activity of CD73. Therefore, it is a valuable tool for studying the role of CD73 in immune regulation and its potential as a therapeutic target⁵. This clone has been utilized for both in vivo and in vitro CD73 blockade, contributing significantly to our understanding of how CD73 impacts immune responses and tumor microenvironments⁶. CD73 is a key player in the tumor microenvironment, and inhibiting its activity has been suggested as a potential strategy for cancer immunotherapy⁷. Tumors exploit CD73 to generate adenosine, which then suppresses T-cell responses against the tumor. By targeting CD73 and inhibiting its function, it is believed that tumorigenesis can be reduced, and T-cell-directed therapies can be enhanced⁸.

CD73 is expressed on subsets of T and B lymphocytes, with the highest expression on B cells and CD8+ T cells.

Nucleoside 5' monophosphate

1. Resta R, Thompson LF. Cell Signal. 1997;9(2):131-139.
2. Resta R, Yamashita Y, Thompson LF. Immunol Rev. 1998;161:95-109.
3. Thomson LF, Ruedi JM, Glass A, et al. Tissue Antigens. 1990;35(1):9-19.
4. Minor M, Alcedo KP, Battaglia RA, Snider NT. Am J Physiol Cell Physiol. 2019;317(6):C1079-C1092.
5. Roh M, Wainwright DA, Wu JD, Wan Y, Zhang B. Curr Opin Pharmacol. 2020;53:66-76.
6. Piccione EC, Mikesell G, Daine-Matsuoka B, Walter K, Miller R, McCaffery I. Cancer Research.2017;77(13_Supplement):5577.
7. Ghalamfarsa G, Kazemi MH, Raoofi Mohseni S, et al. Expert Opin Ther Targets. 2019;23(2):127-142.
8. Beavis PA, Stagg J, Darcy PK, Smyth MJ. Trends Immunol. 2012;33(5):231-237.
9. Zhang F, Li R, Yang Y, et al. Immunity. 2019;50(3):738-750.e7.
10. Allard B, Turcotte M, Spring K, Pommey S, Royal I, Stagg J. Int J Cancer. 2014;134(6):1466-1473.
11. Allard B, Pommey S, Smyth MJ, Stagg J. Clin Cancer Res. 2013;19(20):5626-5635.
12. Yamashita Y, Hooker SW, Jiang H, et al. Eur J Immunol. 1998;28(10):2981-2990.